Cadrenal Therapeutics Stock (NASDAQ:CVKD)
Previous Close
$13.10
52W Range
$8.74 - $22.90
50D Avg
$13.41
200D Avg
$14.97
Market Cap
$26.36M
Avg Vol (3M)
$28.44K
Beta
0.99
Div Yield
-
CVKD Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.